Article

Production of Recombinant Human EGFR CR2 Domain and Generation of Monoclonal Antibodies Discriminating The R and K Variants.

2021-12-10

Abstract excerpt

<h4>Background: </h4> The epidermal growth factor receptor (EGFR) was the first molecular marker to be targeted successfully in monoclonal antibodies-based cancer immunotherapy. The human EGFR displays two common natural genetic variants (R521K) located in the molecule extracellular CR2 domain. This polymorphism affects the outcome of cancer immunotherapy using anti-EGFR mAbs. <h4>Results: </h4>: In this paper, we...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: cf4a74dc-3ae4-5ff2-be57-b0a0b4209850
DOI: 10.21203/rs.3.rs-1132248/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Production of Recombinant Human EGFR CR2 Domain and Generation of Monoclonal Antibodies Discriminating The R and K Variants.DOI 10.21203/rs.3.rs-1132248/v1Read

Development of an EGFRvIII specific recombinant antibodySemantic proximity Read

Transgenic goats producing an improved version of cetuximab in milkSemantic proximity Read

Bioactivity of Recombinant Humanized Monoclonal Antibody Against HER2 and Its Mechanism of Action on Ovarian CancerSemantic proximity Read

T cells expressing a HER2-specific chimeric antigen receptor as treatment for breast cancerSemantic proximity Read

EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan.Semantic proximity Read

Optimization strategies for expression of a novel bifunctional anti-PD-L1/TGFBR2-ECD fusion protein.Semantic proximity Read

Affinity maturation, humanization, and co-crystallization of a rabbit anti-human ROR2 monoclonal antibody for therapeutic applicationsSemantic proximity Read

Generation of Murine Carcinoma Models with Functional Heterologous HER1 and/or HER2 Receptors for In Vivo Study of Specific TherapiesSemantic proximity Read

Isolation and characterization of a novel human scFv inhibiting EGFR vIII expressing cancers.Semantic proximity Read

Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric ReceptorSemantic proximity Read

HER2+ mCRC patients with exon 20 R784G substitution mutation do not respond to the cetuximab therapy.Semantic proximity Read

A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency.Semantic proximity Read